|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inflammation, oxidative stress and renin angiotensin system in atherosclerosis显示文摘Atherosclerosis is a chronic inflammatory disease associated with cardiovascular dysfunction including myocardial infarction, unstable angina, sudden cardiac death, stroke and peripheral thromboses. It has been predicted that atherosclerosis will be the primary cause of death in the world by 2020. Atherogenesis is initiated by endothelial injury due to oxidative stress associated with cardiovascular risk factors including diabetes mellitus, hypertension, cigarette smoking, dyslipidemia, obesity, and metabolic syndrome. The impairment of the endothelium associated with cardiovascular risk factors creates an imbalance between vasodilating and vasoconstricting factors, in particular, an increase in angiotensin Ⅱ(Ang Ⅱ) and a decrease in nitric oxide. The renin-angiotensin system(RAS), and its primary mediator Ang Ⅱ, also have a direct influence on the progression of the atherosclerotic process via effects on endothelial function, inflammation, fibrinolytic balance, and plaque stability. Anti-inflammatory agents [statins, secretory phospholipase A2 inhibitor, lipoprotein-associated phospholipase A2 inhibitor, 5-lipoxygenase activating protein, chemokine motif ligand-2, C-C chemokine motif receptor 2 pathway inhibitors, methotrexate, IL-1 pathway inhibitor and RAS inhibitors(angiotensin-converting enzyme inhibitors)], Ang Ⅱ receptor blockers and ranin inhibitors may slow inflammatory processes and disease progression. Several studies in human using anti-inflammatory agents and RAS inhibitors revealed vascular benefits and reduced progression of coronary atherosclerosis in patients with stable angina pectoris; decreased vascular inflammatory markers, improved common carotid intima-media thickness and plaque volume in patients with diagnosed atherosclerosis. Recent preclinical studies have demonstrated therapeutic efficacy of vitamin D analogs paricalcitol in Apo E-deficient atherosclerotic mice. | Kazim Husain Wilfredo Hernandez Rais A Ansari Leon Ferder | 2015 | World Journal of Biological Chemistry2015，6，3： | 84 |
| 2 | Update on cerebral small vessel disease: a dynamic whole-brain disease显示文摘Cerebral small vessel disease(CSVD)is a very common neurological disease in older people.It causes stroke and dementia,mood disturbance and gait problems.Since it is difficult to visualise CSVD pathologies in vivo,the diagnosis of CSVD has relied on imaging findings including white matter hyperintensities,lacunar ischaemic stroke,lacunes,microbleeds,visible perivascular spaces and many haemorrhagic strokes.However,variations in the use of definition and terms of these features have probably caused confusion and difficulties in interpreting results of previous studies.A standardised use of terms should be encouraged in CSVD research.These CSVD features have long been regarded as different lesions,but emerging evidence has indicated that they might share some common intrinsic microvascular pathologies and therefore,owing to its diffuse nature,CSVD should be regarded as a‘whole-brain disease’.Single antiplatelet(for acute lacunar ischaemic stroke)and management of traditional risk factors still remain the most important therapeutic and preventive approach,due to limited understanding of pathophysiology in CSVD.Increasing evidence suggests that new studies should consider drugs that target endothelium and blood–brain barrier to prevent and treat CSVD.Epidemiology of CSVD might differ in Asian compared with Western populations(where most results and guidelines about CSVD and stroke originate),but more community-based data and clear stratification of stroke types are required to address this. | Yulu Shi Joanna M Wardlaw | 2016 | Stroke & Vascular Neurology2016，1，3： | 74 |
| 3 | ^(131)I治疗格雷夫斯甲亢指南(2021版)显示文摘格雷夫斯甲状腺功能亢进症(Graves′hyperthyroidism,GH)是一种常见的自身免疫性内分泌疾病,其发病率在经历上升后,近年逐渐趋于稳定。^(131)I、抗甲状腺药物(antithyroid drugs,ATD)和手术均为甲状腺功能亢进症(简称甲亢)的一线治疗方法。3种方法治疗后患者生活质量无明显差异,可根据患者的病情、意愿、可利用的医疗条件进行个体化选择。^(131)I疗效确切、临床结局可预期、安全、方便。^(131)I治疗的目标是使患者达到非甲亢状态(non-hyperthyroid status),即恢复正常甲状腺功能;或发生甲状腺功能减退症(简称甲减)后补充甲状腺激素以达到并维持正常甲状腺功能,二者之一均为达到治疗目标。 | 中华医学会核医学分会 李林 李思进 | 2021 | 中华核医学与分子影像杂志2021，41，4： | 44 |
| 4 | Erianin,a novel dibenzyl compound in Dendrobium extract,inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis显示文摘Ferroptosis,a novel form of programmed cell death,is characterized by iron-dependent lipid peroxidation and has been shown to be involved in multiple diseases,including cancer.Stimulating ferroptosis in cancer cells may be a potential strategy for cancer therapy.Therefore,ferroptosis-inducing drugs are attracting more attention for cancer treatment.Here,we showed that erianin,a natural product isolated from Dendrobium chrysotoxum Lindl,exerted its anticancer activity by inducing cell death and inhibiting cell migration in lung cancer cells.Subsequently,we demonstrated for the first time that erianin induced ferroptotic cell death in lung cancer cells,which was accompanied by ROS accumulation,lipid peroxidation,and GSH depletion.The ferroptosis inhibitors Fer-1 and Lip-1 but not Z-VAD-FMK,CQ,or necrostatin-1 rescued erianin-induced cell death,indicating that ferroptosis contributed to erianin-induced cell death.Furthermore,we demonstrated that Ca^(2+)/CaM signaling was a critical mediator of erianin-induced ferroptosis and that blockade of this signaling significantly rescued cell death induced by erianin treatment by suppressing ferroptosis.Taken together,our data suggest that the natural product erianin exerts its anticancer effects by inducing Ca^(2+)/CaMdependent ferroptosis and inhibiting cell migration,and erianin will hopefully serve as a prospective compound for lung cancer treatment. | Peng Chen Qibiao Wu Jiao Feng Lili Yan Yitian Sun Shuiping Liu Yu Xiang Mingming Zhang Ting Pan Xiaying Chen Ting Duan Lijuan Zhai Bingtao Zhai Wengang Wang Ruonan Zhang Bi Chen Xuemeng Han Yicong Li Liuxi Chen Ying Liu Xingxing Huang Ting Jin Wenzheng Zhang Hong Luo Xiaohui Chen Yongqiang Li Qiujie Li Guohua Li Qin Zhang Lvjia Zhuo Zuyi Yang Huifen Tang Tian Xie Xiaoping Ouyang Xinbing Sui | 2020 | Signal Transduction and Targeted Therapy2020，5，1： | 42 |
| 5 | Role of nonsteroidal anti-inflammatory drugs in the prevention of post-ERCP pancreatitis:a meta-analysis显示文摘BACKGROUND:The role of prophylactic nonsteroidal anti- inflammatory drugs(NSAIDs)for reduction of pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP)is debated.We performed a meta-analysis of all published randomized controlled trials to evaluate the efficacy of NSAIDs in the prevention of post-ERCP pancreatitis. DATA SOURCES:Searches were conducted in the databases PubMed,EMBASE and the Cochrane Library. Six randomized clinical trials that fulfilled the inclusion criteria and addressed the clinical questions of this analysis were further assessed.Data were extracted by two independent observers according to predetermined criteria. RESULTS:The risk of pancreatitis was lower in the NSAID group than in the placebo group(OR:0.46,95%CI:0.32 to 0.65,P<0.0001).Two hours after ERCP,prophylactic administration of NSAIDs was associated with a lower serum amylase level(WMD:-91.09,95%CI:-149.78 to-32.40, P=0.002),but there was no difference in mean 24-hour serum amylase values(WMD:-379.00,95%CI:-805.75 to 47.76,P=0.08).No deaths or NSAID-related complications were noted. CONCLUSIONS:Prophylactic administration of NSAIDs can reduce the incidence of post-ERCP pancreatitis; this administration in patients undergoing ERCP is recommended.Further randomized controlled trials are required before its introduction into routine care. | Dai, Hui-Fen Wang, Xiao-Wen Zhao, Kui | 2009 | Hepatobiliary & Pancreatic Diseases International2009，8，1： | 38 |
| 6 | 非甾体抗炎药不良反应的临床研究显示文摘 | 蒋宗滨 | 2006 | 中国疼痛医学杂志2006，12，4： | 36 |
| 7 | Role of dietary polyphenols in the management of peptic ulcer显示文摘Peptic ulcer disease is a multifactorial and complex disease involving gastric and duodenal ulcers.Despite medical advances,the management of peptic ulcer and its complications remains a challenge,with high morbidity and death rates for the disease.An accumulating body of evidence suggests that,among a broad reach of natural molecules,dietary polyphenols with multiple biological mechanisms of action play a pivotal part in the management of gastric and duodenal ulcers.The current review confirmed that dietary polyphenols possess protective and therapeutic potential in peptic ulcer mediated by:improving cytoprotection,re-epithelialization,neovascularization,and angiogenesis; up-regulating tissue growth factors and prostaglandins; down-regulating anti-angiogenic factors; enhancing endothelial nitric oxide synthasederived NO; suppressing oxidative mucosal damage; amplifying antioxidant performance,antacid,and antisecretory activity; increasing endogenous mucosal defensive agents; and blocking Helicobacter pylori colonization associated gastric morphological changes and gastroduodenal inflammation and ulceration.In addition,anti-inflammatory activity due to downregulation of proinflammatory cytokines and cellular and int e r c e llular adhe s ion age nt s,s uppr e s s ing leukocyte-endothelium interaction,inhibiting nuclear signaling pathways of inflammatory process,and modulating intracellular transduction and transcription pathways have key roles in the anti-ulcer action of dietary polyphenols.In conclusion,administration of a significant amount of dietary polyphenols in the human diet or as part of dietary supplementation along with conventional treatment can result in perfect security and treatment of peptic ulcer.Further welldesigned preclinical and clinical tests are recommended in order to recognize higher levels of evidence for the confirmation of bioefficacy and safety of dietary polyphenols in the management of peptic ulcer. | Mohammad Hosein Farzaei Mohammad Abdollahi Roja Rahimi | 2015 | World Journal of Gastroenterology2015，21，21： | 34 |
| 8 | Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy显示文摘Low-dose aspirin(LDA) is clinically used for the prevention of cardiovascular and cerebrovascular events with the advent of an aging society.On the other hand,a very low dose of aspirin(10 mg daily) decreases the gastric mucosal prostaglandin levels and causes significant gastric mucosal damage.The incidence of LDAinduced gastrointestinal mucosal injury and bleeding has increased.It has been noticed that the incidence of LDA-induced gastrointestinal hemorrhage has increased more than that of non-aspirin non-steroidal anti-inflammatory drug(NSAID)-induced lesions.The pathogenesis related to inhibition of cyclooxygenase(COX)-1 includes reduced mucosal flow,reduced mucus and bicarbonate secretion,and impaired platelet aggregation.The pathogenesis related to inhibition of COX-2 involves reduced angiogenesis and increased leukocyte adherence.The pathogenic mechanisms related to direct epithelial damage are acid back diffusion and impaired platelet aggregation.The factors associated with an increased risk of upper gastrointestinal(GI) complications in subjects taking LDA are aspirin dose,history of ulcer or upper GI bleeding,age > 70 years,concomitant use of non-aspirin NSAIDs including COX-2-selective NSAIDs,and Helicobacter pylori(H.pylori) infection.Moreover,no significant differences have been found between ulcer and non-ulcer groups in the frequency and severity of symptoms such as nausea,acid regurgitation,heartburn,and bloating.It has been shown that the ratios of ulcers located in the body,fundus and cardia are significantly higher in bleeding patients than the ratio of gastroduodenal ulcers in patients taking LDA.Proton pump inhibitors reduce the risk of developing gastric and duodenal ulcers.In contrast to NSAIDinduced gastrointestinal ulcers,a well-tolerated histamine H2-receptor antagonist is reportedly effective in prevention of LDA-induced gastrointestinal ulcers.The eradication of H.pylori is equivalent to treatment with omeprazole in preventing recurrent bleeding.Continuous aspirin therapy for patients with gastrointestinal bleeding may increase the risk of recurrent bleeding but potentially reduces the mortality rates,as stopping aspirin therapy is associated with higher mortality rates.It is very important to prevent LDA-induced gastroduodenal ulcer complications including bleeding,and every effort should be exercised to prevent the bleeding complications. | Junichi Iwamoto Yoshifumi Saito Akira Honda Yasushi Matsuzaki | 2013 | World Journal of Gastroenterology2013，19，11： | 29 |
| 9 | Virus against virus:a potential treatment for 2019-nCov(SARS-CoV-2)and other RNA viruses显示文摘The novel coronavirus,2019-nCov(named as SARS-CoV-2 by ICTV Coronaviridae Study Group on February 12,2020),causes severe respiratory illness1 and has been spreading around the world rapidly.2 As of February 14,2020,there are over 64,000 confirmed cases with 1,384 deaths.This raises an urgent need for an effective treatment of the deadly disease.However,current antiviral drugs have limited effects on 2019-nCov(SARS-CoV-2). | Tuan M.Nguyen Yang Zhang Pier Paolo Pandolfi | 2020 | Cell Research2020，30，3： | 30 |
| 10 | 老年人非甾体抗炎药相关上消化道出血的临床特征显示文摘 | 和芳 张泰昌 | 2006 | 中华消化内镜杂志2006，23，1： | 27 |
| 11 | Pyroptosis: mechanisms and diseases显示文摘Currently,pyroptosis has received more and more attention because of its association with innate immunity and disease.The research scope of pyroptosis has expanded with the discovery of the gasdermin family.A great deal of evidence shows that pyroptosis can affect the development of tumors.The relationship between pyroptosis and tumors is diverse in different tissues and genetic backgrounds.In this review,we provide basic knowledge of pyroptosis,explain the relationship between pyroptosis and tumors,and focus on the significance of pyroptosis in tumor treatment.In addition,we further summarize the possibility of pyroptosis as a potential tumor treatment strategy and describe the side effects of radiotherapy and chemotherapy caused by pyroptosis.In brief,pyroptosis is a double-edged sword for tumors.The rational use of this dual effect will help us further explore the formation and development of tumors,and provide ideas for patients to develop new drugs based on pyroptosis. | Pian Yu Xu Zhang Nian Liu Ling Tang Cong Peng Xiang Chen | 2021 | Signal Transduction and Targeted Therapy2021，6，4： | 26 |
| 12 | 非甾体抗炎药临床作用及副作用研究新进展显示文摘非甾体抗炎药(non-steroid anti-inflammtory drugs,NSAIDs)是众所周知的急、慢性风湿性疾病的治疗一线药,据估计全球大约有5亿人在使用NSAIDs,是仅次于抗生素、维生素的第三大类药。它的使用历史可以追溯到19世纪中叶,在一百年中,它从单一的水杨酸制剂发展成为7大类。近百个品种的大家族。然而,有关它的作用机制及临床应用的研究却远没有止步,大量新药也在不断研发之中。因此,作为临床医生需不断了解其研究进展以掌握最新成果。 | 朱华 邹峥 | 2007 | 江西医药2007，42，3： | 22 |
| 13 | 类风湿性关节炎的研究进展显示文摘类风湿性关节炎(Rheumatoid Arthrits.RA)是以关节滑膜慢性炎症为主的自身免疫性疾病,能引起关节肿痛。继而导致软骨破坏,关节间隙变窄,晚期关节畸形,最终出现不同程度的残疾。根据统计表明,RA在全世界均有发病,平均发病率为1%。而我国患病率为0.3%-0.4%。苫未及时诊治,70%患者2年后可致残.平均寿命缩短10~15年。在临床上为了防止和减缓关节的破坏和改善患者的长期患病状况,在过去的几卜年里都是趋向于应用改善疾病的抗风湿药物(disease—modifying anti—rheumatic drugs,DMARDs),得到了很好的疗效. | 王银山 | 2008 | 中国现代医药杂志2008，10，10： | 21 |
| 14 | WJH 6^(th) Anniversary Special Issues(7): Nonalcoholic fatty liver disease Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease显示文摘Non-alcoholic fatty liver disease affects approximately one-third of the population worldwide, and its incidence continues to increase with the increasing prevalence of other metabolic disorders such as type 2 diabetes. As non-alcoholic fatty liver disease can progress to liver cirrhosis, its treatment is attracting greater attention. The pathogenesis of non-alcoholic fatty liver disease is closely associated with insulin resistance and dyslipidemia, especially hypertriglyceridemia. Increased serum levels of free fatty acid and glucose can cause oxidative stress in the liver and peripheral tissue, leading to ectopic fat accumulation, especially in the liver. In this review, we summarize the mechanism underlying the progression of hepatic steatosis to steatohepatitis and cirrhosis. We also discuss established drugs that are already being used to treat non-alcoholic fatty liver disease, in addition to newly discovered agents, with respect to their mechanisms of drug action, focusing mainly on hepatic insulin resistance. As well, we review clinical data that demonstrate the efficacy of these drugs, together with improvements in biochemical or histological parameters. | Hye-jin Yoon Bong Soo Cha | 2014 | World Journal of Hepatology2014，6，11： | 20 |
| 15 | State-of-the-Art management of knee osteoarthritis显示文摘Osteoarthritis(OA) is the most common type of arthritis found in the United States' population and is also the most common disease of joints in adults throughout the world with the knee being the most frequently affected of all joints. As the United States' population ages along with the increasing trends in obesity prevalence in other parts of the world, it is expected that the burden of OA on the population, healthcare system, and overall economy will continue to increase in the future without making major improvements in managing knee OA. Numerous therapies aim to reduce symptoms of knee OA and continued research has helped to further understand the complex pathophysiology of its disease mechanism attempting to uncover new potential targets for the treatment of OA. This review article seeks to evaluate the current practices for managing knee OA and discusses emerging therapies on the horizon. These practices include non-pharmacological treatments such as providing patient education and self-management strategies, advising weight loss, strengthening programs, and addressing biomechanical issues with bracing or foot orthoses. Oral analgesics and anti-inflammatories are pharmacologicals that are commonly used and the literature overall supports that some of these medications can be helpful for managing knee OA in the short-term but are less effective for long-term management. Additionally, more prolonged use significantly increases the risk of serious associated side effects that are not too uncommon. Diseasemodifying osteoarthritis drugs are being researched as a treatment modality to potentially halt or slow disease progression but data at this time is limited and continued studies are being conducted to further investigate their effectiveness. Intra-articular injectables are also implemented to manage knee OA ranging from corticosteroids to hyaluronans to more recently plateletrich plasma and even stem cells while several other injection therapies are presently being studied. The goal of developing new treatment strategies for knee OA is to prolong the need for total knee arthroplasty which should be utilized only if other strategies have failed. High tibial osteotomy and unicompartmental knee arthroplasty are potential alternatives if only a single compartment is involved with more data supporting unicompartmental knee arthroplasty as a good treatment option in this scenario. Arthroscopy has been commonly used for many years to treat knee OA to address degenerative articular cartilage and menisci, however, several high-quality studies have shown that it is not a very effective treatment for the majority of cases and should generally not be considered when managing knee OA. Improving the management of knee OA requires a multi-faceted treatment approach along with continuing to broaden our understanding of this complex disease so that therapeutic advancements can continue to be developed with the goal of preventing further disease progression and even potentially reversing the degenerative process. | Kenton H Fibel Howard J Hillstrom Brian C Halpern | 2015 | World Journal of Clinical Cases2015，3，2： | 19 |
| 16 | Update in version 2021 of CSCO guidelines for colorectal cancer from version 2020显示文摘Colorectal cancer(CRC) is one of the major cancers threatening life and health of Chinese residents. According to the latest data released by the National Cancer Center in2015(1), there were 387,000 new cases and 187,100 deaths of CRC in China, accounting for 9.87% and 8.01% of all malignancies. The first version of the Chinese Society of Clinical Oncology(CSCO) guidelines was released in April2017, and has been updated annually based on the latest clinical research data and the availability of new drugs(2-4). Here, we present the main updates of the 2021 version compared to 2020 version. | Caixia Dong Yuwei Ding Shanshan Weng Guichao Li Yanqing Huang Hanguang Hu Zhen Zhang Suzhan Zhang Ying Yuan | 2021 | Chinese Journal of Cancer Research2021，33，3： | 19 |
| 17 | 中药联合肝动脉化疗栓塞术治疗原发性肝癌系统评价的再评价显示文摘目的:评价中药联合经肝动脉化疗栓塞术治疗原发性肝癌系统评价的方法学偏倚及其结论的可靠性。方法:计算机检索Cochrane图书馆、Pub Med、Guideline、中国生物医学文献数据库、中国期刊全文数据库与万方数据库,收集高质量中药联合经肝动脉化疗栓塞术治疗原发性肝癌的系统评价文献进行再评价。结果:共纳入12篇(项)系统评价。结果显示,中药联合肝动脉化疗栓塞治疗原发性肝癌可提高瘤体客观疗效、延长患者生存时间、提高生存质量,减少术后不良反应发生,且无严重中药相关不良反应报道。结论:中药联合经肝动脉化疗栓塞术治疗原发性肝癌的临床疗效显著优于单纯行经肝动脉化疗栓塞术,且安全性较好。 | 顾露 吴冬梅 谢坪 | 2016 | 中国药房2016，27，15： | 18 |
| 18 | Non-steroidal anti-inflammatory drugs:What is the actual risk of liver damage?显示文摘Non-steroidal anti-inflammatory drugs (NSAIDs) constitute a family of drugs, which taken as a group, represents one of the most frequently prescribed around the world. Thus, not surprisingly NSAIDs, along with antiinfectious agents, list on the top for causes of DrugInduced Liver Injury (DILI). The incidence of liver disease induced by NSAIDs reported in clinical studies is fairly uniform ranging from 0.29/100 000 [95% confidence interval (CI): 0.17-051] to 9/100 000 (95% CI: 6-15). However, compared with these results, a higher risk of liver-related hospitalizations was reported (3-23 per 100 000 patients). NSAIDs exhibit a broad spectrum of liver damage ranging from asymptomatic, transient, hyper-transaminasemia to fulminant hepatic failure. However, under-reporting of asymptomatic, mild cases, as well as of those with transient liver-tests alteration, in conjunction with reports non-compliant with pharmacovigilance criteria to ascertain DILI and flawed epidemiological studies, jeopardize the chance to ascertain the actual risk of NSAIDs hepatotoxicity. Several NSAIDs, namely bromfenac, ibufenac and benoxaprofen, have been withdrawn from the market due to hepatotoxicity; others like nimesulide were never marketed in some countries and withdrawn in others. Indeed, the contro-versy concerning the actual risk of severe liver disease persists within NSAIDs research. The present work intends (1) to provide a critical analysis of the dissimilar results currently available in the literature concerning the epidemiology of NSAIDS hepatotoxicity; and (2) to review the risk of hepatotoxicity for each one of the most commonly employed compounds of the NSAIDs family, based on past and recently published data. | Fernando Bessone | 2010 | World Journal of Gastroenterology2010，16，45： | 16 |
| 19 | Cyclooxygenase-2 and the inflammogenesis of breast cancer显示文摘Cohesive scientific evidence from molecular, animal, and human investigations supports the hypothesis that constitutive overexpression of cyclooxygenase-2(COX-2) is a ubiquitous driver of mammary carcinogenesis, and reciprocally, that COX-2 blockade has strong potential for breast cancer prevention and therapy. Key findings include the following:(1) COX-2 is constitutively expressed throughout breast cancer development and expression intensifies with stage at detection, cancer progression and metastasis;(2) essential features of mammary carcinogenesis(mutagenesis, mitogenesis, angiogenesis, reduced apoptosis, metastasis and immunosuppression) are linked to COX-2-driven prostaglandin E2(PGE-2) biosynthesis;(3) upregulation of COX-2 and PGE-2 expression induces transcription of CYP-19 and aromatase-catalyzed estrogen biosynthesis which stimulates unbridled mitogenesis;(4) extrahe-patic CYP-1B1 in mammary adipose tissue converts paracrine estrogen to carcinogenic quinones with mutagenic impact; and(5) agents that inhibit COX-2 reduce the risk of breast cancer in women without disease and reduce recurrence risk and mortality in women with breast cancer. Recent sharp increases in global breast cancer incidence and mortality are likely driven by chronic inflammation of mammary adipose and upregulation of COX-2 associated with the obesity pandemic. The totality of evidence clearly supports the supposition that mammary carcinogenesis often evolves as a progressive series of highly specific cellular and molecular changes in response to induction of constitutive overexpression of COX-2 and the prostaglandin cascade in the 'inflammogenesis of breast cancer'. | Randall E Harris Bruce C Casto Zachary M Harris | 2014 | World Journal of Clinical Oncology2014，5，4： | 15 |
| 20 | 难治性癫痫持续状态治疗策略显示文摘难治性癫痫持续状态(refractory status epileptics,RSE)是指足够剂量的初始抗癫痫药物(anti—epileptic drugs,AEDs),如苯二氮革类药物后续另一种AEDs仍无法终止的癫痫持续发作和(或)脑电图持续痫性放电。在中国,无论在神经内科、神经外科、急诊科还是重症医学科,RSE都是危及生命的急危重症。 | 宿英英 | 2015 | 中华神经科杂志2015，48，3： | 15 |
您所在的机构暂未开通此部分的功能，请联系管理员